Clinical Trials Browser

Phase 1/2 × utomilumab × Clear all

NCT03217747 2025-10-23

Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies

Phase 1/2 Active not recruiting

173 enrolled 28 charts

Neoplasm Metastasis, Prostatic Neoplasms

NCT03318900 2024-11-07

T-Cell Infusion, Aldesleukin, and Utomilumab in Treating Patients With Recurrent Ovarian Cancer

Phase 1/2 Completed

5 enrolled 8 charts

Ovarian Neoplasms